started · updated
GLP-1 medications face scrutiny over shortages and health risks
The rising popularity of GLP-1 medications, such as Ozempic and Wegovy, has sparked significant medical discussion regarding their use for weight loss versus diabetes management. While these drugs effectively suppress appetite and slow gastric emptying, experts warn that they should not replace comprehensive health policies addressing nutrition and physical activity.
Medical authorities have raised several concerns. The European Medicines Agency (EMA) has noted that increased demand for weight loss has led to shortages, potentially reducing availability for diabetes patients. Additionally, the FDA has recorded hundreds of reports of adverse effects related to semaglutide and tirzepatide. A UK study highlighted a potential risk during anesthesia, noting that GLP-1 users may face an 11-fold higher risk of gastric regurgitation or pulmonary aspiration.
Research also indicates physiological trade-offs. Studies suggest that 15% to 40% of weight lost on these medications may consist of lean muscle mass rather than just fat. On a scientific level, the discovery of the biologically active form of GLP-1, credited to researcher Svetlana Mojsov, remains a cornerstone of these modern therapies. While new research explores how these drugs might assist lymphatic function, medical professionals emphasize that they are not a cure for conditions like lipedema and must be used under strict clinical supervision.
Entities
European Medicines Agency · FDA · Mounjaro · Ozempic · Svetlana Mojsov · Wegovy
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] Increased demand for GLP-1 drugs since 2022 has caused shortages of certain medications. skopje1.mk · denesen.mk · srpskainfo.com
- [○ 1 SOURCE] Between 15% and 40% of weight lost while using GLP-1 drugs may consist of lean body mass, including muscle. www.farmer.pl
- [● 3 SOURCES] The EMA warns that using Ozempic for weight loss may reduce drug availability for patients with diabetes. skopje1.mk · denesen.mk · srpskainfo.com
- [● 2 SOURCES] The FDA received over 900 reports of adverse effects related to semaglutide and over 730 related to tirzepatide by May. skopje1.mk · denesen.mk
- [○ 1 SOURCE] Patients taking GLP-1 drugs have over 11 times higher risk of gastric regurgitation or pulmonary aspiration during anesthesia. www.glasistre.hr
- [● 2 SOURCES] Scientist Svetlana Mojsov made key contributions to the discovery of the biologically active form of GLP-1. press24.mk · sitel.com.mk
- [● 3 SOURCES] Ozempic works by acting on the center for satiety in the brain and slowing gastric emptying. kozarski.com · www.archynewsy.com · www.timesnownews.com
- [○ 1 SOURCE] Adults receiving weekly semaglutide consumed 35% fewer calories during test meals compared to placebo groups. www.archynewsy.com